Vermillion Shareholder Alleges Medicare Denying Over 80 Percent of OVA1 Reimbursement Claims | GenomeWeb

This story originally ran on Dec. 22.

By Adam Bonislawski

A Vermillion shareholder this week accused the company’s management of not disclosing high Medicare denial rates for reimbursement of its ovarian cancer diagnostic OVA1.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.